Revised forecast
Fiscal year ending March 2026 · Full yearThe bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
In the cosmetics business, the effect of expanding sales from upfront investments was below expectations, while in the Beauty & Wellness business, the launch of strategic products was delayed due to malfunctions in some product functions. In the regenerative medicine-related business, results were affected by changes in the product mix and higher depreciation and selling, general and administrative expenses related to newly established facilities. In new businesses and businesses at the research and development stage, poor performance and upfront investment costs pressured earnings. Impairment losses were also recognized in the regenerative medicine-related, Sustainable, and AI and Technology businesses.
Impairment losses were recognized. The businesses covered were the regenerative medicine-related, Sustainable, and AI and Technology businesses. Amount: Not disclosed.
| Item | Details |
|---|---|
| Net Sales | ¥2,840 million → ¥2,370 million（-16.5%） |
| Operating profit | ¥-483 million → ¥-774 million |
| Ordinary income | ¥-495 million → ¥-961 million |
| Profit attributable to owners of the parent | ¥-499 million → ¥-1,276 million |
| Net income per share | -6.57 yen and sen → -16.52 yen and sen |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Period Covered | Full year |
| Previous-period results | Consolidated revenue: ¥2,253 million; consolidated operating loss: ¥208 million; consolidated ordinary loss: ¥228 million; net loss attributable to owners of the parent: ¥276 million; loss per share: ¥4.36 |
| Reason for the revision | In the cosmetics business, the effect of expanding sales from upfront investments was below expectations, while in the Beauty & Wellness business, the launch of strategic products was delayed due to malfunctions in some product functions. In the regenerative medicine-related business, results were affected by changes in the product mix and higher depreciation and selling, general and administrative expenses related to newly established facilities. In new businesses and businesses at the research and development stage, poor performance and upfront investment costs pressured earnings. Impairment losses were also recognized in the regenerative medicine-related, Sustainable, and AI and Technology businesses. |
| Details and amount of extraordinary loss | Impairment losses were recognized. The businesses covered were the regenerative medicine-related, Sustainable, and AI and Technology businesses. Amount: Not disclosed. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the cosmetics business and other businesses, the effect of expanding sales from upfront investments in advertising and sales promotion expenses was below expectations. The launch of strategic products was delayed after defects were identified following mass production. Results were also affected by changes in the product mix, higher depreciation and selling, general and administrative expenses related to newly established facilities, poor performance and upfront investment costs in new businesses and research and development businesses, and the recognition of impairment losses.